Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 49

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 8
Chunk 49
---
 1,139,360  
     1,966,258 
  
    Total operating costs 
     1,146,476  
     6,006,178  
     8,404,168  
     9,336,739 
  
    Interest income (expense), net 
     44,182  
     15,445  
     52,156  
     (4,297,604)
  
    Segment net loss 
    $(1,102,294) 
    $(5,990,733) 
    $(8,352,012) 
    $(13,634,343)

Note
7. Subsequent Events

ATM
Offering

On
October 9, 2025, the Company sold a total of 550,000 shares of its common stock, no par value, in block sales to institutional investors,
at an average price of $1.90 per share, through its at-the-market equity offering facility. Net proceeds totaled $1,003,200, after deducting
fees and expenses. The trades for the Offering were facilitated through Rodman & Renshaw, via the StockBlock platform.

Letter
of Intent

On
October 17, 2025, the Company executed a binding Letter of Intent (the “LOI”) to acquire TELI Pharmaceuticals, Inc., a
related party company, securing worldwide rights to its lead investigational therapy, Telomir-1. The transaction aligns
Telomir’s U.S. rights with TELI’s ex-U.S. intellectual property portfolio, which includes filings across Europe, Canada,
Mexico, China, Japan, South Korea, India, Israel, Australia, Argentina, Uruguay, Taiwan, and the United Arab Emirates-creating a
single global owner positioned to capture the full commercial value of Telomir-1 across oncology, metabolic, and age-related
diseases. The proposed transaction also includes
up to $5 million in potential contributions, in cash or cash equivalents, from certain TELI shareholders over the duration of the collaboration,
with $1 million due at closing, $2 million upon IND acceptance, and $2 million upon Phase 1/2 initiation. The transaction is subject to
shareholder and board approval.

13

Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The
following discussion and analysis should be read in conjunction with the Condensed Financial